Bristol-Myers joins forces with Vanderbilt U. against Parkinson's disease

Bristol-Myers Squibb ($BMY) has teamed up with neuroscientists at Vanderbilt University to find new drugs for Parkinson's disease. The drug giant is paying for the Vanderbilt Center for Neuroscience Drug Discovery to hunt down new treatments that home in on the mGluR4 receptor to treat the neurological disease. The program has previously won support from The Michael J. Fox Foundation for Parkinson's Research, and now Bristol has promised the university an upfront payment and potential milestone fees and royalties. Bristol gains rights to develop and sell drugs discovered through the alliance. Article

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.